Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Status:
Completed

Trial end date:
2006-05-01

Target enrollment:

Participant gender:

This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Phase 2

Novartis Pharmaceuticals